Common Stock, par value $0.001 per share
- Symbol
- QNCX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Oct 9, 2026
Current Report · Items 7.01, 9.01 · 8-K/A
IRulya Therapeutics Inc.
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The Exhibit 99.2 attached hereto is a replacement of the Exhibit 99.2 furnished with the Original Filing. The information contained in this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by refere…
Company context
Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
Current securities
Historical securities (1)
Registered securities in this filing
QUINCE THERAPEUTICS, INC. · 8-K/A · Filed 2026-05-18
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
The Exhibit 99.2 attached hereto is a replacement of the Exhibit 99.2 furnished with the Original Filing. The information contained in this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.2 2 d135388dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeks Phase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────── Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET ───────────────────────────────────────────────────────────────────── South San Francisco, CA, May 18, 2026 - Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented at the American …
Open exhibit ↗